652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
Aung Naing(The University of Texas MD Anderson Cancer Center), Richard D. Kim(Moffitt Cancer Center), Sara Ferrando‐Martínez(National Institutes of Health), Mohamed H. Derbala(The University of Texas MD Anderson Cancer Center), Hirva Mamdani(Wayne State University), Allison Bierly, Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Julie A. Murphy, Jack Goon, Meredith Pelster(Mary Crowley Cancer Research Center), Samuel Darko, Siyoung Lee(Konkuk University), Se Hwan Yang, Byung Ha Lee(OncoImmune (United States)), L Gorelik, Minal Barve(Mary Crowley Cancer Research Center)
Cited by 1
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338